Citations

1. Bauters TGM, et al. (2002). Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. American Journal of Obstetrics and Gynecology, 187(3): 569–574.

2. Ferris DG, et al. (2002). Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstetrics and Gynecology, 99(3): 419–425.

3. Ressel GW (2002). CDC releases 2002 guidelines for treating STDs: Part I. Diseases characterized by vaginal discharge and PID. American Family Physician, 66(9): 1777–1778.

4. Marrazzo J (2002). Vulvovaginal candidiasis. BMJ, 325(7364): 586–587.

5. Kessel KV, et al. (2003). Common complementary and alternative therapies for yeast vaginitis and bacterial vaginosis: A systematic review. Obstetrical and Gynecological Survey, 58(5): 351–358.

6. U.S. Department of Health and Human Services (2002). Sexually Transmitted Diseases Treatment Guidelines 2002 (CDC Publication Vol. 51, No. RR-6), pp. 45–48. Atlanta: U.S. Department of Health and Human Services.

7. Eschenbach DA (2003). Vaginitis section of Pelvic infections and sexually transmitted diseases. In JR Scott et al., eds., Danforth's Obstetrics and Gynecology, 9th ed., pp. 585–589. Philadelphia: Lippincott Williams and Wilkins.

8. Pirotta M, et al. (2004). Effect of lactobacillus in preventing post-antibiotic vulvovaginal candidiasis: A randomised controlled trial. BMJ, 329(7465):548.

9. Spence D (2003). Candidiasis (vulvovaginal). Clinical Evidence (12): 2490–2508.